Related Experiment Videos
Detection of bone marrow micrometastasis.
1Laboratory of Immunology, Research Centre of Medical Science, Tsinghua University, China. chenyh@mail.tsinghua.edu.cn
Hybridoma
|December 22, 1999
Summary
Detecting single cancer cells is challenging. A new antibody test found micrometastases in bone marrow of non-small cell lung cancer patients, aiding early diagnosis.
Area of Science:
- Oncology
- Immunohistochemistry
- Cancer Diagnostics
Background:
- Detecting single metastasizing tumor cells is a significant challenge in cancer diagnostics.
- Early identification of micrometastastasis is crucial for non-small cell lung cancer (NSCLC) patient prognosis.
Purpose of the Study:
- To evaluate the utility of a monoclonal antibody (MAb A45-B/B3) for detecting single tumor cells and micrometastases in NSCLC patients.
- To assess the feasibility of using immunocytochemistry for early diagnosis of bone marrow micrometastasis in NSCLC.
Main Methods:
- Utilized a monoclonal antibody (MAb A45-B/B3) that recognizes human cytokeratin.
- Applied immunocytochemical methods to analyze bone marrow samples from 24 NSCLC patients at the time of primary tumor surgery.
- Quantified cytokeratin-positive cells in bone marrow aspirates.
Main Results:
- Identified single tumor cells and micrometastases in bone marrow samples from 9 out of 24 NSCLC patients.
- Detected cytokeratin-positive cells ranging from 1 to 14 per 5 x 10(5) cells.
- Observed a unique cluster of nine connected tumor cells in one sample, indicating potential cell aggregation.
Conclusions:
- The MAb A45-B/B3 immunocytochemical technique is effective for identifying single tumor cells and micrometastases.
- This method shows promise as an early diagnostic tool for bone marrow micrometastasis in non-small cell lung cancer patients.